GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Price-to-Owner-Earnings

Bio-Techne (BSP:T1CH34) Price-to-Owner-Earnings : 56.17 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Price-to-Owner-Earnings?

As of today (2024-05-11), Bio-Techne's share price is R$13.48. Bio-Techne's Owner Earnings per Share (TTM) ended in Mar. 2024 was R$0.24. It's Price-to-Owner-Earnings for today is 56.17.


The historical rank and industry rank for Bio-Techne's Price-to-Owner-Earnings or its related term are showing as below:

BSP:T1CH34' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.35   Med: 42.31   Max: 105.91
Current: 56.3

During the past 13 years, the highest Price-to-Owner-Earnings of Bio-Techne was 105.91. The lowest was 21.35. And the median was 42.31.


BSP:T1CH34's Price-to-Owner-Earnings is ranked worse than
68.26% of 167 companies
in the Biotechnology industry
Industry Median: 35.03 vs BSP:T1CH34: 56.30

As of today (2024-05-11), Bio-Techne's share price is R$13.48. Bio-Techne's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was R$0.21. Therefore, Bio-Techne's PE Ratio for today is 65.44.

As of today (2024-05-11), Bio-Techne's share price is R$13.48. Bio-Techne's EPS without NRI for the trailing twelve months (TTM) ended in was R$0.30. Therefore, Bio-Techne's PE Ratio without NRI for today is 44.78.

During the past 13 years, Bio-Techne's highest PE Ratio without NRI was 89.16. The lowest was 21.83. And the median was 40.81.


Bio-Techne Price-to-Owner-Earnings Historical Data

The historical data trend for Bio-Techne's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Price-to-Owner-Earnings Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 88.92 49.69 55.05

Bio-Techne Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.96 55.05 54.24 60.81 50.04

Competitive Comparison of Bio-Techne's Price-to-Owner-Earnings

For the Biotechnology subindustry, Bio-Techne's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Price-to-Owner-Earnings falls into.



Bio-Techne Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bio-Techne's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=13.48/0.24
=56.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Techne  (BSP:T1CH34) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Bio-Techne Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (BSP:T1CH34) Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (BSP:T1CH34) Headlines

No Headlines